Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?
08:35am, Friday, 10'th Oct 2025
Here's why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple be
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
10:15am, Thursday, 09'th Oct 2025
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer
04:31pm, Wednesday, 08'th Oct 2025
The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals' immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease returning af
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Monday, 06'th Oct 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Regeneron Pharmaceuticals catalysts could drive stock higher: analysts
10:11am, Friday, 03'rd Oct 2025
JP Morgan analysts see an “attractive setup” for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares, believing the company's Dupixent and Eylea drugs and cash on hand alone support valuation a
Regeneron: Growth Catalysts Incoming
04:25pm, Tuesday, 30'th Sep 2025
Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
04:05pm, Tuesday, 30'th Sep 2025
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday
Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
01:37pm, Tuesday, 30'th Sep 2025
CNBC's "Halftime Report" team detail their stock picks and final trades.
2 Beaten-Down Stocks to Buy and Hold for a Decade
07:30am, Tuesday, 30'th Sep 2025
Over the past couple of years, Moderna (MRNA 3.39%) and Regeneron Pharmaceuticals (REGN -0.62%) have encountered company-specific headwinds that have sunk their stock prices. The former is down by 75%
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
09:30am, Monday, 29'th Sep 2025
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Regeneron: Strong R&D Pipeline Drives Growth Outlook
09:00am, Saturday, 27'th Sep 2025
Retail investors' fears over the launch of Eylea biosimilars are gradually fading amid the strong performance of Dupixent and Libtayo, actively gaining share in the PD-1 and PD-L1 inhibitors market. S
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-densit
